$29.47
Aptevo Therapeutics is a biotechnology business based in the US. Aptevo Therapeutics shares (APVO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptevo Therapeutics employs 45 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Aptevo Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – APVO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Aptevo Therapeutics stock price (NASDAQ: APVO)
Use our graph to track the performance of APVO stocks over time.Aptevo Therapeutics shares at a glance
Latest market close | $0.32 |
---|---|
52-week range | $0.30 - $3.91 |
50-day moving average | $0.62 |
200-day moving average | $1.64 |
Wall St. target price | $12.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.18 |
Buy Aptevo Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Aptevo Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aptevo Therapeutics price performance over time
Historical closes compared with the close of $0.3165 from 2023-09-27
1 week (2023-09-21) | -5.52% |
---|---|
1 month (2023-08-28) | -18.28% |
3 months (2023-06-28) | -77.71% |
6 months (2023-03-28) | -83.25% |
1 year (2022-09-28) | -90.23% |
---|---|
2 years (2021-09-27) | -98.02% |
3 years (2020-09-28) | 7.5 |
5 years (2018-09-28) | 71.12 |
Aptevo Therapeutics financials
Gross profit TTM | $3.1 million |
---|---|
Return on assets TTM | -57.97% |
Return on equity TTM | -97.17% |
Profit margin | 0% |
Book value | $2.16 |
Market Capitalization | $4 million |
TTM: trailing 12 months
Aptevo Therapeutics share dividends
We're not expecting Aptevo Therapeutics to pay a dividend over the next 12 months.
Have Aptevo Therapeutics's shares ever split?
Aptevo Therapeutics's shares were split on a 1:14 basis on 26 March 2020. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptevo Therapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Aptevo Therapeutics shares which in turn could have impacted Aptevo Therapeutics's share price.
Aptevo Therapeutics share price volatility
Over the last 12 months, Aptevo Therapeutics's shares have ranged in value from as little as $0.3 up to $3.91. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptevo Therapeutics's is 5.2251. This would suggest that Aptevo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aptevo Therapeutics overview
Aptevo Therapeutics Inc. , a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG. APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.
Frequently asked questions
What percentage of Aptevo Therapeutics is owned by insiders or institutions?Currently 1.097% of Aptevo Therapeutics shares are held by insiders and 12.23% by institutions. How many people work for Aptevo Therapeutics?
Latest data suggests 45 work at Aptevo Therapeutics. When does the fiscal year end for Aptevo Therapeutics?
Aptevo Therapeutics's fiscal year ends in December. Where is Aptevo Therapeutics based?
Aptevo Therapeutics's address is: 2401 4th Avenue, Seattle, WA, United States, 98121 What is Aptevo Therapeutics's ISIN number?
Aptevo Therapeutics's international securities identification number is: US03835L2079 What is Aptevo Therapeutics's CUSIP number?
Aptevo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03835L207
More guides on Finder
-
How to buy Discord stock when it goes public
Everything we know about the Discord IPO, plus information on how to buy in.
-
How to buy Tottenham Acquisition I stock
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
-
How to buy TotalEnergies stock
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
-
How to buy Thunder Bridge Acquisition stock
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
-
How to buy Switchback Energy Acquisition Corporation stock
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
-
How to buy Telefonica SA ADR stock
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
-
How to buy Faraday Future stock
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
-
How to buy Phoenix Tree stock
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
-
How to buy Innate Pharma stock
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
-
How to buy HHGregg IncIN stock
Steps to owning and managing HGGG, with 24-hour and historical pricing before you buy.
Ask an Expert